Immune Pharmaceuticals Inc. (Nasdaq: IMNP) signed a letter of intent with Pint Pharma to negotiate an exclusive license by Pint for the rights to commercialize Ceplene in Latin America. The stock price leaped $1.21 to close at $3.65.
Immune Pharmaceuticals signs LOI
April 20, 2017 at 17:03 PM EDT
